Candel Therapeutics (NASDAQ:CADL) Now Covered by Analysts at Jefferies Financial Group

Key Points

• Jefferies initiated coverage of Candel Therapeutics with a “buy” rating and a $25 price target, implying approximately 198% upside from the reported $8.38 share price.
• Analyst sentiment is mixed but leans positive: MarketBeat reports a consensus “Moderate Buy” rating and an average price target of $21.43, alongside two sell ratings and multiple buy recommendations.
• Candel recently reported a quarterly loss of $0.52 per share, missing the $0.24 consensus estimate, and analysts expect a full-year loss of $1.29 per share.

Jefferies Financial Group began coverage on shares of Candel Therapeutics (NASDAQ:CADL - Get Free Report) in a research note issued to investors on Thursday, MarketBeat.com reports. The firm set a "buy" rating and a $25.00 price target on the stock. Jefferies Financial Group's price target would suggest a potential upside of 198.33% from the company's current price.

A number of other research analysts also recently weighed in on the stock. Zacks Research downgraded shares of Candel Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Wednesday, October 14th. UBS Group reissued a "buy" rating on shares of Candel Therapeutics in a research note on Monday, August 17th. Weiss Ratings reissued a "sell (d-)" rating on shares of Candel Therapeutics in a research note on Thursday, October 15th. Stifel Nicolaus initiated coverage on Candel Therapeutics in a report on Monday, July 13th. They issued a "buy" rating and a $22.00 price objective on the stock. Finally, Bank of America raised Candel Therapeutics from a "neutral" rating to a "buy" rating and increased their target price for the company from $12.00 to $18.00 in a report on Monday, September 21st. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $21.43.

Candel Therapeutics Stock Up 0.1%

Shares of CADL stock opened at $8.38 on Thursday. Candel Therapeutics has a fifty-two week low of $4.35 and a fifty-two week high of $14.00. The firm has a market capitalization of $641.24 million, a PE ratio of -5.94 and a beta of -0.32. The company has a debt-to-equity ratio of 0.38, a quick ratio of 16.09 and a current ratio of 16.09. The stock's 50-day simple moving average is $11.18 and its 200-day simple moving average is $9.44.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.28). Equities analysts expect that Candel Therapeutics will post -1.29 earnings per share for the current year.

Insiders Place Their Bets

In other Candel Therapeutics news, CTO Seshu Tyagarajan sold 7,000 shares of the firm's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $12.00, for a total value of $84,000.00. Following the transaction, the chief technology officer directly owned 76,865 shares of the company's stock, valued at $922,380. This trade represents a 8.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 14.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Candel Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Janney Montgomery Scott LLC lifted its position in Candel Therapeutics by 12.6% during the first quarter. Janney Montgomery Scott LLC now owns 30,472 shares of the company's stock worth $149,000 after buying an additional 3,400 shares in the last quarter. Krilogy Financial LLC increased its stake in shares of Candel Therapeutics by 25.3% in the 1st quarter. Krilogy Financial LLC now owns 30,065 shares of the company's stock worth $155,000 after acquiring an additional 6,065 shares during the last quarter. Legal & General Group Plc acquired a new stake in shares of Candel Therapeutics in the 2nd quarter worth $63,000. HB Wealth Management LLC raised its holdings in shares of Candel Therapeutics by 15.3% during the 1st quarter. HB Wealth Management LLC now owns 67,245 shares of the company's stock worth $330,000 after acquiring an additional 8,900 shares during the period. Finally, AXQ Capital LP raised its holdings in shares of Candel Therapeutics by 50.8% during the 2nd quarter. AXQ Capital LP now owns 31,460 shares of the company's stock worth $324,000 after acquiring an additional 10,596 shares during the period. Institutional investors and hedge funds own 13.93% of the company's stock.

About Candel Therapeutics

Candel Therapeutics, Inc is a clinical-stage biopharmaceutical company developing biological immunotherapies designed to stimulate the immune system to recognize and attack cancer. The company's approach uses engineered viral therapies intended to promote immunogenic cell death and generate broader, potentially systemic antitumor immune responses.

Candel's pipeline includes CAN-3110, an investigational oncolytic immunotherapy based on a genetically engineered herpes simplex virus type 1.